{"id":"tiva-neostigmine-70","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased salivation"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL278020","moleculeType":"Small molecule","molecularWeight":"223.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the enzyme acetylcholinesterase, neostigmine prevents the breakdown of acetylcholine, leading to increased acetylcholine concentration in synaptic spaces. This enhances cholinergic neurotransmission at the neuromuscular junction and autonomic nervous system sites. The drug is used to reverse neuromuscular blockade and treat myasthenia gravis by prolonging the action of available acetylcholine.","oneSentence":"Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction and in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:58.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of neuromuscular blockade"},{"name":"Myasthenia gravis"},{"name":"Postoperative ileus and urinary retention"}]},"trialDetails":[{"nctId":"NCT05037006","phase":"PHASE4","title":"Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade","status":"UNKNOWN","sponsor":"Pontificia Universidade Catolica de Sao Paulo","startDate":"2021-10-01","conditions":"Neuromuscular Blockade, Neuromuscular Blockade, Residual","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TIVA"],"phase":"marketed","status":"active","brandName":"TIVA - Neostigmine 70","genericName":"TIVA - Neostigmine 70","companyName":"Pontificia Universidade Catolica de Sao Paulo","companyId":"pontificia-universidade-catolica-de-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction and in the central nervous system. Used for Reversal of neuromuscular blockade, Myasthenia gravis, Postoperative ileus and urinary retention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}